Syncom Formulations (India) Ltd. — Interim / Quarterly Report 2025

Nov 12, 2025

Phiroze Jeejeebhoy Tower,

Mumbai (M.H.) 400 001 BSE CODE:524470

To,

BSE Limited

Dalal Street,

SYNCOM/SE/2025-26 12th November, 2025

Online filing at: www.listing.bseindia.com and https://neaps.nseindia.com/NEWLISTINGCORP/login.jsp

To,

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai- 400051 NSE SYMBOL: SYNCOMF

Subject: Regulation 33(3) of SEBI (LODR) Regulations, 2015 - Submission of Standalone & Consolidated unaudited Financial Results along with Limited Review Report, Statement of Assets and Liabilities and Cash Flow for the quarter and half year ended on 30th September, 2025.

Dear Sir/Ma'am

This is in continuation of our letter no. SYNCOM/SE/2025-26 dated 7th November, 2025 regarding intimation of Board meeting for consideration and approval of Standalone and Consolidated Un-Audited Financial Results for the Quarter/ Half Year ended 30th September, 2025.

Pursuant to Regulation 33(3) of SEBI (LODR) Regulations, 2015, we are pleased to submit the following:

• 1. Standalone and Consolidated Un-Audited Financial Results of the Company for the Quarter/ Half Year ended on 30th September, 2025;
• 1. Standalone and Consolidated Limited Review Report by the Statutory Auditors of the company for the Quarter/ Half Year ended on 30th September, 2025;
• 1. Standalone and Consolidated Un-Audited Statement of Assets and Liabilities for the Half Year ended on 30th September, 2025; and
• 1. Standalone and Consolidated Un-Audited Statement of Cash Flow for the Half year ended on 30th September, 2025.

The aforesaid results were considered and approved by the Board of Directors at its meeting held on Wednesday, 12th November, 2025, which commenced at 3:00 P.M. and concluded at 5:00 P.M

We are also in process of filing the aforesaid financial results in XBRL format within the stipulated time and the same shall also be hosted on the website of the company in due course.

Further, the Financial Results will be published in widely circulated English and Marathi (Vernacular) newspaper in the prescribed format within the stipulated time period.

You are requested to kindly take the unaudited Financial Results, Statement of Assets and Liabilities and Cash Flow along with Limited Review Report, on record for your reference and record.

Thanking You, Yours Faithfully, For, SYNCOM FORMULATIONS (INDIA) LIMITED CS VAISHALI AGRAWAL COMPANY SECRETARY & COMPLIANCE OFFICER Encl: a/a Vaishali Agrawal Digitally signed by Vaishali Agrawal Date: 2025.11.12 17:08:57 +05'30'

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7.Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector -1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :-- L24239MH1988PLC047759

						(Rs.In Lakhs) ( Except EPS)
Ss. No.	Particulars		Quarter Ended		Year to date Ended		Year Ended
			30/09/2025 30/06/2025 30/09/2024 30/09/2025 30/09/2024 31/03/2025
			Unaudited Unaudited Unaudited Unaudited Unaudited				Audited
A	Revente trom Operations	12143.51	11654.69	10149.25	23798.20	18735.68	46284.93
2	Other Income	523.44	601.97	418.35	1125.41	646.32	1719.12
3	{Total Income ( 1+ 2)	12666.95	12256.66	10567.60	24923.61	19382.00	48004.05
4	EXPENSES
	( a) Cost of materials consumed	4642.63	5961.30	6857.57	10603.93	12160.70	27802.93
	( b ) Purchases of Stock-in-Trade ( ¢ ) Changes in inventories of finished goods, Stock-in- Trade	1535.33	1561.93	1260.24	3097.26	1666.32	3947.71
	and work-in-progress	909.36	(616.39)	(1560.83),	292.97	(1824.12)	(1062.24)
	('d) Employee benefits expense	1673.08	1595.44	1240.39	3268.52	2325.15	5217.37
	(e) Finance costs	25.03	23.74	16.22	48.77	54.87	85.02
	( f ) Depreciation and amortization expense	135.00	434.00	130.00	269.00	260.00	519.39
	(9) Other expenses	1510.77	1574.94	1158.89	3085.71	2264.27	5028.63
	Total expenses ( 4)	10431.20	10234.96	9102.48	20666.16	16907.19	41538.81
5	Profit/(loss) before exceptional items and tax (3- 4)	2235.75	2021.70	1465.12	4257.45	2474.84	6465.24
6	Exceptional Items	0.00	4.13	(0.24)	4.13	(0.24)	0.58
7	Profit/(loss) before tax (5-6)	2235.75	2025.83	1464.88	4261.58	2474.57	6465.82
8	Tax expense:
	(1) Current tax (2) Deferred tax	522.00 29.64	431,60 21.30	348.55 21.33	953.60 50.94	592.32 24.39	1445.26 133.38
9	Profit (Loss) for the period from continuing operations (7-
	}3)	1684.11	1572.93	1095.00	3257.04	1857.86	4887.18
10	Profit/(loss) from discontinued operations Tax expense of discontinued operations	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00
tt 12	Profit/(loss) from Discontinued operations (after tax) (10-11)
		0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/(loss) for the period (9+ 12)	1684.11	1572.93	1095.00	3257.04	1857.86	4887.18
14	Other Comprehensive Income
	A(/)Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to	0.00	0,00	0.00	0.00	0.00	0.00
	profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (/) Items that will be reclassified to profit or loss	(5.58)	403.84	391.88	398.26	667.81	458.02
	(ii) Income tax relating to items that will be reclassified to profil]
	or loss	0.00	0.00	0.00	0.00	0.00	0.00
15	Total Comprehensive Income for the period (XIll+XIV) (Comprising Profit (Loss) and Other Comprehensive}
	Income for the period)	1678.53	1976.77	1486.88	3655.30	2525.67	5345.20
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
7	Reserves excluding revaluation reserves				2	=	24590.38
18	Earnings per equity share (for continuing operation)
	(1) Basic	0.18	0.21	0.16	0.39	0.27	0.57
19	(2) Diluted JEarnings per equity share (for discontinued operation):	0.18	0.21	0.16	0.39	0.27	0.57
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
20	Earnings per equity share (for discontinued & continuing} loperations)
	(1) Basic	0.18	0.21	0.16	0.39	0.27	0.57
	(2) Diluted	0.18	0.214	0.16	0.39	0.27	0.57

Place: Indore

SYNCOM FORMULATIONS (INDIA) LIMITED

Regd.Off :- 7, Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail: finance@sfil.in, Website:- www.sfilin, CIN - L24239MH1988PLC047759

	STANDALONE STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND HALF YEARLY UNAUDITED RESULTS
	Particulars		Quarter Ended			Year to date Ended
S.No.		30/09/2025	30/06/2025	30/09/2024	30/09/2025	30/09/2024	Ended 31/03/2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Segment Revenue
	ja) Pharmaceuticals Drugs & Formulations	12567.69}	12062.52)	10218.43	24630.21	18803.76	46,784.92)
	lb) Trading of Commodities	0.00}	104.56	251.10}	104.56)	383.51	825.84)
	ic) Renting of Property	99.26	ba	98.07,	188.84}	194.73	393.29}
	Total Segment Revenue	12666.95	1 2256.66)	10567.60)	24923.61	19382.00]	48,004.05)
	Less: Inter Segment Revenue	0. oo]	0.00]	0.00)	+
	[Revenue from Operations	12666.95}	12256.66)	0567.60)	24923.61	19382.00)	48,004.05)
2	Segment Results Profit(+)/Loss(-) before tax
	land interest from each segment
	ja) Pharmaceuticals Drugs & Formulations	2167.52	1960.52!	1382.69	4128.04)	2338.05]	6,169.91
	lb) Trading of Commodities	0.00}	1.35}	8.40)	1.35}	12.79}	20,35}
	Ic) Renting of Property	93.26	83.57]	90.01	176.83}	178.60	360.59
	Total Profit before tax	2260.78)	2045.44)	1481.10)	4306.22)	2529.44)	6,550.84)
	Less: i) Interest	25.03}	23.74)	16.22}	48.77,	54.87]	85.02!
	ii) Other Un-allocable Expenditure	0.00}	0.00)	0.00	0,00)	4	+
	Profit before tax	2235.75	2021.70}	1464.88]	4257.45]	2474.57!	6,465.82) —
	ia 3 (Segment Asset-Segment Liabilities)
	'Segment Asset
	a) Pharmaceuticals Drugs & Formulations	40128.78]	39302.09	3123408)	40128.78}	31234.08}	35,752.01
	lb) Trading of Commodities	251.35)	259.18}	971.86]	251.35	971.86)	448.67)
	Ic) Renting of Property	4733.44}	4733.44)	4733.45}	4733.44]	4733.4:	4,767.98]
	Total Segment Asset	45113.57	44294.71	36939,39	45113.57	36939.39]	40,968.66
	lUn-allocable Assets	0.00}	0.00)	0.00	+	S	+
	Net Segment Asset	45113.57}	44294.71	36939.39)	45113.57	36939,39}	40,968.66)
	Segment Liabilities
	la) Pharmaceuticals Drugs & Formulations	7332.38}	8185.83}	5432.16]	7332.38}	5432.16)	6,754.47]
	lb) Trading of Commodities	2.11	8.36	243.87]	2.11	243,87]	82.76
	Ic) Renting of Property	133.40}	133.36}	92.52}	133.40}	92.52	141.04)
	Total Segment Liabilities	7467.89}	8327.55]	5768.55}	7467.89]	5768.55	6,978.27]
	Un-allocable Liabilities	0.00}	0.00	0.00	a		7 q
	Net Segment Liabilities	7467.89}	8327.55]	5768.55]	7467.89)	5768.55]	6,978.27,

Notes:

1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/11/2025,

2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.

4 The Standalone Statement of Assets and Liabilities as at 30th September, 2025 and the Standalone Statement of Cash Flow is provided as an annexure to this statement. 5 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th September 2025. The report does not have any impact on the above results and notes which needs explanation.

6 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

Date: 12/11/2025

Place: Indore c , Syncom Formulations (indja) Limited eo Ankit Kedarmal Bankda Chairman & Wholetime Director Din : 02359461

SYNCOM FORMULATIONS (INDIA) LIMITED
Regd. Off -- 7, Niraj Industrial Estate, Off Mahakali Caves Road, Andheri (E) Mumbai-400093
NCOM Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775
E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759
Standalone Statement of Assets & Liabilities as at 30/09/2025
Particulars	30/09/2025	31/03/2025
Rs. In Lacs	unaudited	Audited
ASSETS
Non-current assets
(a) Property, Plant and Equipment	7,669.64	7,752.61
(b) Capital Work in Progress	800.95	=
(c) Intangible assets	4.72	4.72
(d) Investment Property	4,733.44	4,733.44
(e) Financial Assets
(i) Investments	385.26	364.82
(ii) Fixed Deposits & Accrued Interest	1,489.76	1,218.67
(iii) Deposits (f) Other Non Current Assets	72.26	66.62
Current assets	71.00	81.58 =
(a) Inventories (b) Financial Assets	2,845.77	4,129.29
(i) Investments
(ii) Trade Receivables	14,381.89	8,921.64
(iil) Cash And Cash Equivalents	10,063.40	10,694.43
(iv) Bank Balances other than (iii) above	23.66	69.23
(v) Deposits	- 367.35	= 353.22
(vi) Loans & Advances	617.69	539.29
(d) Other Current Assets	1,586.78	2,039.10
Total"	45,113.57	40,968.66
EQUITY AND LIABILITIES
Equity
(a) Equity Share Capital	9,400.00
(b) Other Equity	28,245.68	9,400.00
Liabilities		24,590.38
Non Current Liabilities
(a) Financial Liabilities
(i) Trade and other Deposits
(b) Provisions	133.40 459.38	133.35 416.84
(c) Deferred Tax Liabilities (Net)	681.99	631.05
Current liabilities
(a) Financial liabilities
(i) Borrowings	29.96	404.32
(ii) Trade Payables
Total Outstanding Dues of Micro Enterprises and Small Enterprises	667.37	2,278.89
Total Outstanding Dues of Creditors other than Micro Enterprises and Small Enterprises	361.27	1,993.30
(iii) Other Financial Liabilities	212.75	213.00
(b) Other Current Liabilities	860.49	495.68
(c) Provisions	661.28	411.85
Total	45,113.57	40,968.66

Place: Indore Date: 12/11/2025

com Formulations (India} Limited g ——_ Ankit Kedarmal Bankda Chairman & Wholetime Director Din : 02359461

Syncom Formulations (India) Limited

Regd. Off :- 7,Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector -1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN -- L24239MH1988PLC047759

Standalone Cash Flow Statement for the period ended September 30,2025

Decrease In CA & Increase in CL: Add
Increase in CA & Decrease in CL: Deduct
Particulars	30/09/2025 Amount	31/03/2025 Amount
Cash Flow from Operating Activities
Profit before extraordinary item and tax	4,257.45	6,465.24
Adjustments for:
Gain on Sale of Machinery /(Loss on Sale of Vehicle)	-	0.58
Gain/(Loss) on Actuarial valuation of employee benefits	(6.20)	(28.91)
Depreciation	269.00	519.39
Depreciation Written Back	-	(39.14)
Finance Costs	48.77	85.02
Other Income	(1,092.70)	(1,633.53)
Operating Profit before working capital changes	3,476.32	5,368.65
Changes in Working Capital
Inventory	1,283.52	(2,021.14)
Trade Receivables	631.03	(1,372.97)
Loans & Advances	(78.40)	- (109.96)
Other Current Assets	438.19	(1,140.49)
Trade Payables	156.45	2,849.09
Other Financial Liabilities	(0.25)	(0.62)
Other Current Liabilities	364.81	137.64
Short Term Provisions	249.43	66.39
Changes in Working Capital	3,044.78	(1,592.06)
Cash Generated from Operations before Tax	6,521.10	3,776.59
Less: Income Tax Paid	953.60	1,445.26
Net Cash From Operating Activities	5,567.50	2,331.33
Cash Flow from Investing Activities
Change in Property Plant and Equipment, Intangible Assets and Capital Work in Progress	(882.89)	(BoRoS)
Change in Investment Property		_
Change in Fixed Deposit & Accrued Interest	(271.09)	(183.82)
Change in Deposits	(5.64)	(14.72)
Change in Other Non Current Assets	10.58	(61.02)
Change in Trade & Other Deposits	0.05	(38.25)
Other Income	1,092.70	1,633.53
Change in Investment	(5,076.23)	(2,177.67)
Net Cash from Investing Activities	(5,232.48)	(1,837.88)
Cash Flow from Financing Activities
Finance Costs	(48.77)	(85.02)
Change in Long Term Liabilities	42.54	86.46
Issue of Warrants & Share capital	=	2
Dividend Paid	=	&
Borrowings	(374.36)	(6,760.71)
Net Cash from Financing Activities	(380.59)	(6,759.27)
Net Decrease in Cash & Cash Equivalents	(45.57)	(6,265.82)
Cash & Cash Equivalents at the beginning of the Period	69.23	6,335.05
Cash & Cash Equivalents at the End of Period	23.66	69.23
Place: Indore		ulations (Inia) Limited
Date: 12/11/2025		oe
		Ankit Kedarmal Bankda
		rman & Wholetime Director
		Din : 02359461

SANJAY MEHTA & ASSOGIATES

Ch artered Accountants

Limited Revie* Report on Un-audited Standalone Financial Results for the Quarter & Half year ended 30th September, 2025 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

To,

The Board of Directors SYNCOM FORMULATIONS ONDIA) LIMITED Indore (M.P.)

We have reviewed the accompanying statement of Standalone Unaudited Financial Results of SYNCOM FORMULATIONS (INDIA) LIMITED ("the Comprtry"), for the period ended September, 30, 2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended including relevant circular issued by the SEBI from time to time.

This statement which is the responsibility of the Company's Management and has been approvecl by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("lND AS 34"), prescribed under Section 133 of tlie Companies Act, 2013, and other Accounting principles generally accepteci in India and in compliance with the Regulation 33 of tlie SEBI (LODR) Regulations,20l5, as amended, including relevant circulars issued by the SEBI from time to time. Our responsibility' is to issue a report on these Financial Staternents based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 241tt, "Review oJ'Interim Financial Information performed b),the Independent Auditor cf the Entity", issuetJ by the Institute of Chartered Accountants of India. This standard requires that we plan and perfonn the review to obtain moderate assurance as to whetherthe financial statements are free of material misstatement. A review is timited primarily to inquiries of company personnel and analyical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of'Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirernents) Regulations,20l5,including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Sanjay Mehta &Associates Chartered Accoun FRN: 011524C Date: 12 November,2025 CA Manish Mittal (Partner) M. No. 079452 UDIN : 2507 9 452BMI H EC37J0 pxc ! (r,,roone)E K\Z'

Place: Indore

cOM Regd. Off - 7, Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website- www.sfil.in, CIN :- L24239MH1988PLC047759

CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTERLY AND HALF YEARLY ENDED 30TH SEPTEMBER, 2025

Ss. No.	Particulars	Quarter Ended			Year to date ended		Year Ended
		30-09-2025 Unaudited	30-06-2025 Unaudited	30-09-2024 Unaudited	30-09-2025 Unaudited	30-09-2024 Unaudited	31-03-2025 *Audited
1	Revenue from Operations	12171,74	11690,17	10231.42	23861.91	18860.30	46501.26
2	Other Income	525.05	603.47	414,92	1128.52	645.42	1743.40
3	_[fotal income (7+ 2)	12696.79	12293.64	10646.34	24990.43	19505.72	48244.66
4	EXPENSES ( a) Cost of materials consumed ( b ) Purchases of Stock-in-Trade ( c ) Changes in inventories of finished goods, Stock-in- Trade!	4642.63 1529.13	5961.30 1568.13	6857.57 1266.24	10603.93 3097.26	12160.70 1694.85	27802.93 3996.75
	land work-in-progress	903.71	(612.48)	(1543.72)	291,23	(1824.12)	(1066.15)
	(d) Employee benefits expense	1673.08	1595.44	1240.39	3268.52	2325.15	5217.37
	fe): Finance costs	26.49	25.08	15.96	51.57	54.99	86.49
	( f) Depreciation and amortization expense	135.00	134,00	130,00	269,00	260.00	519.39
	(9) Other expenses	1583.10	1597.06	1194.83	3180.16	2338.87	5137.19
	Total expenses (4)	10493.14	10268.53	9161.27	2076.67	17010.44	41693.97
	5 _ Profit/(loss) before. exceptional items and tax (3- 4)	2203.65	2025.11	1485.07	4228.76	2498.28	6550.69
6	{Exceptional items	0.00	413	0.00	4.13	(0.24)	0.58
rf	Profit/(loss) before tax (5-6)	2203.65	2029.24	1485.07	4232.89	2495.04	6551.27
8	Tax expense: (1) Current tax (2) Deferred tax	513.90 29.64	432.50 21.30	352.92 21.33	946.40 50.94	596.82 24.39	1474.43 133.38
t:)	Profit (Loss) for the period from continuing operations (7-8)	1660.11	1575.44	1110.82	3235.56	1873.83	4943.46
10 1	Profit((loss) from discontinued operations		0.00	0,00		0.00	0.00
42.	'Tax expense of discontinued operations Profit/(loss) from Discontinued operations (after tax) (10-11)		0.00	0,00		0.00	0.00
13	Profit/(loss) for the period (9+ 12)	1660.11	0.00 1575.44	0.00 1110.82	3235.55	0.00 1873.83	0.00 4943.46
14	Other Comprehensive income A(/)Items that will not be reclassified to profit or loss	0.00	0.00	0.00		0.00	0.00
	(i) Income tax relating to items that will not be reclassified to} profit or loss	0.00	0.00
	: B (/) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit	(5.58)	403.84	0.00 391.88	398.26	0,00 667.81	0,00 458.02
	or loss	0.00	0.00	0.00		0.00	0.00
15	Total Comprehensive Income for the period (XIll+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	1654.53	1979.28	1502.70	3633.81	2541.64	5401.48
16	Paid up Share Capital of the Company (Face Value 1/-)	9400.00	9400.00	9400.00	9400.00	9400.00	9400.00
17	Reserves excluding revaluation reserves			a		ra	24815.76
18	Eamings per equity share (for continuing operation):
19	(1) Basic (2) Diluted Earnings per equity share (for discontinued operation):	0.18 0.18	0.21 0.21	0.16 0.16	0.39 0.39	0.27 0.27	0.57 0.57
20	(1) Basic (2) Diluted Earnings per equity share (for discontinued & continuing loperations)	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00
	(1) Basic (2) Diluted	0.18 0.18	0.21 0.21	0.16	0.39 0.39	0.27 0.27	0.57 0.57

Date: 12/11/2025 Lif

Place: Indore Syncom Formulations (India) Limited

a" Ankit Kedarmal Bankda Chairman & Wholetime Director Din : 02359461

NCOM

- ~ SYNCOM FORMULATIONS (INDIA) LIMITED

Regd. Off :- 7,Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dnar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN '- L24239MH1988PLC047759

CONSOLIDATED STATEMENT OF SEGMENT WISE REVENUE, RESULTS ALONG WITH QUARTERLY AND HALF YEARLY UNAUDITED RESULTS

	payuaulas	Quarter Ended			Year to date ended		Year Ended
ag		30-09-2025 Unaudited	Unaudited	Unaudited	30-06-2025 30-09-2024 30-09-2025 30-09-2024 31-03-2025 Unaudited	Unaudited	*Audited
4	Segment Revenue
	a) Pharmaceuticals Drugs & Formulations	12,597.98	12,099.95)	10,298.07)	24697.93}	18928.38	47,027.33
	b) Trading of Commodities	-	104,56)	251.10}	104,56	383.51	825.84
	c) Renting of Property	98.81	89.13)	97.17]	187.94]	193.83}	391.49
	Total Segment Revenue	12,696.79	12,293.64)	10,646.34)	24,990.43]	19,505.72	48,244.66}
	Less: Inter Segment Revenue			+		0.00}	+
	Revenue from Operations	12,696.79}	12,293.64)	10,646.34)	24,990.43)	19,505.72	48,244.66]
2	[Segment Results Profit(+)/Loss(-) before tax
	and interest from each segment
	ja) Pharmaceuticals Drugs & Formulations	2,131.33	1,965.72)	1,403.29}	4097.05)	2359.54]	6,258.62]
	lb) Trading of Commodities	0.00	4.35]	8.40)	1.35)	42.79)	20.35
	ic) Renting of Property	98.81	83.12)	89.11	181.93	177.70}	358.79
	Total Profit before tax	2,230.14	2,050.19)	1,500.80	4,280.33)	2,550.03	6,637.76
	Less: i) Interest a	26.49	25.08)	15.96)	51.57	54.99}	86.49
	ii) Other Un-allocable Expenditure			+		0.00}	+
	Profit before tax	2,203.65)	2,025.11	1,484.84)	4,228.76	2,495.04)	6,561.27
3	(Segment Asset-Segment Liabilities)
	Segment Asset
	a) Pharmaceuticals Drugs & Formulations	40,623.55	39,780.77	31,539.20}	40623.55)	31639.20	36,111.42
	b) Trading of Commodities	251.35	259.18}	971.86}	251.35	971.86]	448.67
	ic) Renting of Property	4,733.44	4,733.44)	4,733.45	4733.44)	4733.45)	4,767.98
	Total Segment Asset	45,608.34)	44,773.39)	37,244.51	45,608.34)	37,244.51	41,328.07
	Un-allocable Assets			+		0.00	-
	Net Segment Asset	45,608.34	44,773.39]	37,244.51	45,608.34	37,244.51	41,328.07]
	Segment Liabilities
	a) Pharmaceuticals Drugs & Formulations	7,623.26	8,436.63}	9,552.20)	7623.26}	\$552.20	6,888.49
	Ib) Trading of Commodities	2.11	8.36	243.87)	244	243.87)	82.76
	Ic) Renting of Property	133.40	133.36]	92.52)	133,40)	92.52)	141.04
	Total Segment Liabilities	7,758.77,	8,578.35)	5,888.59)	7,758.77	5,888.59)	7,112.29}
	Un-allocable Liabilities		+	4		0.00)	-
	[Net Segment Liabilities	7,758.77,	8,578.35	5,888.59)	7,758.77]	5,888.59	7,112.29]

|Notes:-

1 The above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 12/11/2025

2 These above results have been prepared in compliance with the Indian Accounting Standard (referred to as "Ind AS") as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies (Indian Accounting Standards) Rules 2015 as amended from time to time.

3 The company is operating in 3 segments i.e. (a) Pharmaceuticals Drugs & Formulations (b) Trading of Commodities (c) Renting of Property, particulars of segment wise results are given as required.

4 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th September, 2025. The report does not have any impact on the above results and notes which needs explanation.

5 Previous period figures have been regrouped/reclassified wherever necessary to confirm to this period classification.

6 The Company currently have 3 (three) Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd., Sante Biotech Pvt. Ltd. And Vincit Biotech International Pvt. Ltd. 7 The Consolidated Statement of Assets and Liabilities as at 30th September, 2025 and Consolidated Statement of saa a led as an annexure to this statement

Date: 12/11/2025

Oe, i) Lig * Place: Indore RC: ao Ankit Kedarmal Bankda Chairman & Wholetime Director Din : 02359461

SYNCOM FORMULATIONS (INDIA) LIMITED
COM	Regd.Off :- 7,Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (FE) Mumbai-400093
Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775 E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN :- L24239MH1988PLC047759
CONSOLIDATED Statement of Assets & Liabilities as at 30/09/2025
Particulars	30/09/2025	31/03/2025
Rs. In Lacs	Unaudited	*Audited
ASSETS
Non-current assets
(a) Property, Plant and Equipment	7,669.64	7,752.61
(b) Capital Work in Progress	800.95	-
(c) Intangible assets	4.72	4.72
(d) Investment Property	4,733.44	4,733.44
(e) Financial Assets		-
(i) Investments	382.26	361.82
(ii) Fixed Deposits & Accrued Interest	1,505.22	1,330.52
(iii) Deposits	72.26	66.62
(f) Other Non Current Assets	71.00	81.58
Current assets		=
(a) Inventories	2,851.42	4,133.20
(b) Financial Assets		-
(i) Investments (ii) Trade Receivables	14,381.89	8,921.64
(ili) Cash And Cash Equivalents	10,224.22	10,754.85
(iv) Bank Balances other than (iii) above	21.53	71.20
(v) Deposits	100.00	-
(vi) Loans & Advances	367.35 624.53	353.22
(d) Other Current Assets	1,791.91	543.53
Total	45,608.34	2,219.12 41,328.07
EQUITY AND LIABILITIES
Equity
(a) Equity Share Capital	9,400.00
(b) Other Equity	28,449.57	9,400.00 24,815.76
Liabilities
Non Current Liabilities		-
(a) Financial Liabilities		=
(i) Trade and other Deposits	133.40	- 133.35
(b) Provisions	459.38	416.84
(c) Deferred Tax Liabilities (Net)	681.99	631.05
Current liabilities		"5
(a) Financial liabilities		-
(i) Borrowings	69.70	458.36
(ii) Trade Payables
Total Outstanding Dues of Micro Enterprises and Small Enterprises	667.37	2,281.33
- Hic ee Dues of Creditors other than Micro Enterprises	3,963.42	1 998.41
(iii) Other Financial Liabilities	212.74	213.00
(b) Other Current Liabilities (c) Provisions	911.67	561.62
Total	659.10	418.35
C	in), 45,608.34 rte	41,328.07
Place: Indore	= cm	''kormulations (India), Limited
Date: 12/11/2025	i LY Singnat®	7, Wwe?
		Ankit Kedarmal Bankda irman & Wholetime Director
		Din : 02359461

Syncom Formulations (India) Limited

Regd.Off :- 7,Niraj Industrial Estate, Off Mahakali Caves Road,Andheri (E) Mumbai-400093

Works:- 256-257, Sector - 1, Pithampur, Dist: Dhar-454775

E Mail:- finance@sfil.in, Website:- www.sfil.in, CIN - L24239MH1988PLC047759

Consolidated Cash Flow Statement for the period ended 30th September 2025

Decrease In CA & Increase in CL: Add Increase in CA & Decrease in CL: Deduct (Rs. In Lacs ) Parinntoee 30/09/2025 31/03/2025 Amount Amount Cash Flow from Operating Activities Profit before extraordinary item and tax 4,228.76 6,550.69 Adjustments for: " Gain on Sale of Machinery / (Loss on Sale of Vehicle) 0.58 Gain/(Loss) on Actuarial valuation of employee benefits (6.20) (28.91) Depreciation 269.00 519.39 Depreciation Written Back - (39.14) Finance Costs 51.57 86.49 Other Income (1,095.81) (1,657.81) Operating Profit before working capital changes 3,447.32 §,431.29 Changes in Working Capital . Inventory 1,281.78 (2,025.05) Trade Receivables 530.63 (425.01) Loans & Advances (81.00) (118.75) Other Current Assets 427.21 (1,116.35) Trade Payables 351.05 1,865.35 Other Financial Liabilities (0.26) (0.62) Other Current Liabilities 350.05 148.92 Short Term Provisions 240.75 55.26 Changes in Working Capital 3,100.21 (1,613.25) Cash Generated from Operations before Tax 6,547.53 3,818.04 Less: Income Tax Paid 946.40 1,474.43 Net Cash From Operating Activities 5,601.13 2,343.61 Cash Flow from Investing Activities Change in Property Plant and Equipment, Intangible Assets and Capital Work in Progress (See.63) (985.88) Change in Fixed Deposit & Accrued Interest (274.70) (190.64) Change in Deposits (14.13) (14.72) Change in Other Non Current Assets 10.58 (61.02) Change in Trade & Other Deposits (5.64) (38.25) Other Income 1,095.81 1,657.81 Change in Investment (5,076.23) (2,177.67) Net Cash from Investing Activities (5,247.16) (1,820.42) Cash Flow from Financing Activities Finance Costs (51.57) (86.49) Change in Long Term Liabilities 42.59 86.46 Borrowings (388.66) (6,790.30) Net Cash from Financing Activities (397.64) (6,790.33) Net Decrease in Cash & Cash Equivalents (43.67) (6,267.14) Cash & Cash Equivalents at the beginning of the Period 71.20 6,338.34 Cash & Cash Equivalents at the End of Period 27.53 71.20 Place: Indore

Date: 12/11/2025 ohm

Ankit Kedarmal Bankda ' Chairman & Wholetime Director Din : 02359461

SANJAY MEHTA & ASSOGIATES

Ch artered Accountants

Limited Review Report on Un-audited Consolidated Financial Results for the Quarter and Half Year ended 30'h September,2025 pursuant to Regulation 33 of the SEBI (LODR) Regulationso 2015

To, Thc Board of Directors SYNCOM FORMULATIONS (INDIA) LIMITED Indore (M.P.)

• l. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of SYNCOM FORMULATIONS (INDIA) LIMITED ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the period ended September 30.2025 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (LODR) Regulations,20l5. as amended including relevant circular issued by the SEBI from time to time.
• 1. This statement which is the responsibility of the Company's Management and has been approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurelnent principles laid down in the Indian Accounting Standard 34 Interim Financial Reporting" ("IND AS 34"), prescribed under Section 133 of the Companies Act,20l3, and other Accounting principles generally accepted in India and in compliance with the Regulation 33 of the SEBI (LODR) Regulations,2015,as amended, including relevant circulars issued by the SEBI fiom time to time. Our responsibility is to issue a report on these Financial Statements based on our revierv.
• 1. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review o./' Interim Financial Informalion per;fbrmed b), the Independenl Auditor of the Enlily", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide iess assurance than an audit. We have not performed an audit and accordingly, we do rrot express an audit opinion.

No.	Name of the Company	with Relationship
		i Holding Com an
I	Sante Biotech Pvt. Ltd.	Whollv Or.vned Subsidi
2.	Synmex Pharma Pvt. Ltd.	Wholly Owneci Subsidi
	Vincit Biotech International Pvt. Ltd.	Wholly Owned Subsidiary

1. Thc Statement includes the results of thc following entity:

1. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2Ol5,including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore Date: 12th November, ²⁰²⁵ CA Manish Mi

For, Sanjay Mehta &Associates Chartered Accountants

(Partner) M. No. 079452 UDIN: 2507 9 452BMIHED13 1 I FRN:011524C ffi KV/